Pages

Event search results

  • Date:17WednesdayOctober 2018

    G-INCPM-Special Seminar - Prof. Rony Seger, Department of Biological Regulation, Weizmann Institute - "Targeting the nuclear translocation of MAPKs as a novel anti-inflammatory and anti cancer therapy"

    More information
    Time
    11:00 - 12:15
    Location
    Nancy and Stephen Grand Israel National Center for Personalized Medicine
    Auditorium
    Organizer
    Department of Biomolecular Sciences
    Contact
    AbstractShow full text abstract about A hallmark of MAPK signaling is their nuclear translocation ...»
    A hallmark of MAPK signaling is their nuclear translocation upon stimulation, which is necessary for their physiological/pathological functions. We have identified two novel, distinct, regulated nuclear translocation mechanisms for ERK1/2 and JNK/p38, of which we made use of as a promising therapeutic approach. We developed a myristoylated, NTS-derived phosphomimetic peptide (EPE peptide), which blocked ERK1/2 nuclear translocation. In culture, the EPE peptide induced apoptosis of melanoma cells, inhibited the proliferation of other cancer cells but had no effect on immortalized cells. Combination of the EPE peptide and the MEK inhibitor had synergistic antitumor activity in mutated NRAS, BRAF and NF1 melanoma and Kras pancreatic cells. In xenograft models, the peptide was significantly more effective than BRAF inhibitors in preventing tumor recurrence of treatment-eradicated melanoma xenografts. We also developed p38-derived myristoylated peptide, termed PERY peptide, which inhibited the importin interaction with JNK1/2 and p38α/β and prevented their nuclear translocation. This peptide affected viability of several breast cancer-derived cell lines, and significantly reduced inflammation and intestinal damage in a mouse model of colitis. Moreover, the peptide inhibited inflammation-induced colorectal cancer in a AOM/DSS mouse model. Taken together, both the cancer and inflammatory models support the use of nuclear translocation of MAPKs as a novel drug target for signaling-related diseases.
    Lecture
  • Date:17WednesdayOctober 2018

    G-INCPM-Special Seminar - Prof. Rony Seger, Department of Biological Regulation, Weizmann Institute - "Targeting the nuclear translocation of MAPKs as a novel anti-inflammatory and anti cancer therapy"

    More information
    Time
    11:00 - 12:15
    Location
    Nancy and Stephen Grand Israel National Center for Personalized Medicine
    Auditorium
    Organizer
    Department of Biomolecular Sciences
    Contact
    AbstractShow full text abstract about A hallmark of MAPK signaling is their nuclear translocation ...»
    A hallmark of MAPK signaling is their nuclear translocation upon stimulation, which is necessary for their physiological/pathological functions. We have identified two novel, distinct, regulated nuclear translocation mechanisms for ERK1/2 and JNK/p38, of which we made use of as a promising therapeutic approach. We developed a myristoylated, NTS-derived phosphomimetic peptide (EPE peptide), which blocked ERK1/2 nuclear translocation. In culture, the EPE peptide induced apoptosis of melanoma cells, inhibited the proliferation of other cancer cells but had no effect on immortalized cells. Combination of the EPE peptide and the MEK inhibitor had synergistic antitumor activity in mutated NRAS, BRAF and NF1 melanoma and Kras pancreatic cells. In xenograft models, the peptide was significantly more effective than BRAF inhibitors in preventing tumor recurrence of treatment-eradicated melanoma xenografts. We also developed p38-derived myristoylated peptide, termed PERY peptide, which inhibited the importin interaction with JNK1/2 and p38α/β and prevented their nuclear translocation. This peptide affected viability of several breast cancer-derived cell lines, and significantly reduced inflammation and intestinal damage in a mouse model of colitis. Moreover, the peptide inhibited inflammation-induced colorectal cancer in a AOM/DSS mouse model. Taken together, both the cancer and inflammatory models support the use of nuclear translocation of MAPKs as a novel drug target for signaling-related diseases.
    Lecture
  • Date:17WednesdayOctober 2018

    G-INCPM-Special Seminar - Prof. Rony Seger, Department of Biological Regulation, Weizmann Institute - "Targeting the nuclear translocation of MAPKs as a novel anti-inflammatory and anti cancer therapy"

    More information
    Time
    11:00 - 12:15
    Location
    Nancy and Stephen Grand Israel National Center for Personalized Medicine
    Auditorium
    Organizer
    Department of Biomolecular Sciences
    Contact
    AbstractShow full text abstract about A hallmark of MAPK signaling is their nuclear translocation ...»
    A hallmark of MAPK signaling is their nuclear translocation upon stimulation, which is necessary for their physiological/pathological functions. We have identified two novel, distinct, regulated nuclear translocation mechanisms for ERK1/2 and JNK/p38, of which we made use of as a promising therapeutic approach. We developed a myristoylated, NTS-derived phosphomimetic peptide (EPE peptide), which blocked ERK1/2 nuclear translocation. In culture, the EPE peptide induced apoptosis of melanoma cells, inhibited the proliferation of other cancer cells but had no effect on immortalized cells. Combination of the EPE peptide and the MEK inhibitor had synergistic antitumor activity in mutated NRAS, BRAF and NF1 melanoma and Kras pancreatic cells. In xenograft models, the peptide was significantly more effective than BRAF inhibitors in preventing tumor recurrence of treatment-eradicated melanoma xenografts. We also developed p38-derived myristoylated peptide, termed PERY peptide, which inhibited the importin interaction with JNK1/2 and p38α/β and prevented their nuclear translocation. This peptide affected viability of several breast cancer-derived cell lines, and significantly reduced inflammation and intestinal damage in a mouse model of colitis. Moreover, the peptide inhibited inflammation-induced colorectal cancer in a AOM/DSS mouse model. Taken together, both the cancer and inflammatory models support the use of nuclear translocation of MAPKs as a novel drug target for signaling-related diseases.
    Lecture
  • Date:17WednesdayOctober 2018

    G-INCPM-Special Seminar - Prof. Rony Seger, Department of Biological Regulation, Weizmann Institute - "Targeting the nuclear translocation of MAPKs as a novel anti-inflammatory and anti cancer therapy"

    More information
    Time
    11:00 - 12:15
    Location
    Nancy and Stephen Grand Israel National Center for Personalized Medicine
    Auditorium
    Organizer
    Department of Biomolecular Sciences
    Contact
    AbstractShow full text abstract about A hallmark of MAPK signaling is their nuclear translocation ...»
    A hallmark of MAPK signaling is their nuclear translocation upon stimulation, which is necessary for their physiological/pathological functions. We have identified two novel, distinct, regulated nuclear translocation mechanisms for ERK1/2 and JNK/p38, of which we made use of as a promising therapeutic approach. We developed a myristoylated, NTS-derived phosphomimetic peptide (EPE peptide), which blocked ERK1/2 nuclear translocation. In culture, the EPE peptide induced apoptosis of melanoma cells, inhibited the proliferation of other cancer cells but had no effect on immortalized cells. Combination of the EPE peptide and the MEK inhibitor had synergistic antitumor activity in mutated NRAS, BRAF and NF1 melanoma and Kras pancreatic cells. In xenograft models, the peptide was significantly more effective than BRAF inhibitors in preventing tumor recurrence of treatment-eradicated melanoma xenografts. We also developed p38-derived myristoylated peptide, termed PERY peptide, which inhibited the importin interaction with JNK1/2 and p38α/β and prevented their nuclear translocation. This peptide affected viability of several breast cancer-derived cell lines, and significantly reduced inflammation and intestinal damage in a mouse model of colitis. Moreover, the peptide inhibited inflammation-induced colorectal cancer in a AOM/DSS mouse model. Taken together, both the cancer and inflammatory models support the use of nuclear translocation of MAPKs as a novel drug target for signaling-related diseases.
    Lecture
  • Date:21SundayOctober 2018

    Memorial Day for Yitzhak Rabin

    More information
    Time
    11:00 - 12:30
    Contact
    Lecture
  • Date:21SundayOctober 2018

    TBA

    More information
    Time
    11:00
    Location
    Sussman Family Building for Environmental Sciences
    M. Magaritz Seminar Room
    Lecturer
    Zvika Steiner
    University of Cambridge
    Organizer
    Department of Earth and Planetary Sciences
    Contact
    Lecture
  • Date:22MondayOctober 2018

    "Composition-Dependent Functions of Biomolecular Condensates"

    More information
    Time
    11:00 - 12:15
    Location
    Gerhard M.J. Schmidt Lecture Hall
    Lecturer
    Prof. Michael Rosen
    UT Southwestern Medical Center
    Organizer
    Faculty of Chemistry
    Contact
    Colloquia
  • Date:22MondayOctober 2018

    G-INCPM - Special Seminar - Dr. Wolfgang Mann, CEO, BlueCatBio GmbH, Germany - "Blue Washer: the most cost-effective tool to improve data quality (z') for adherent cellular assays"

    More information
    Time
    11:00 - 12:15
    Location
    Nancy and Stephen Grand Israel National Center for Personalized Medicine
    Auditorium
    Organizer
    Department of Biomolecular Sciences
    Contact
    AbstractShow full text abstract about Since its introduction in 2015 the BlueWasher has rapidly be...»
    Since its introduction in 2015 the BlueWasher has rapidly become the de-facto standard for media change & cell wash in adherent cellular assays.
    The BlueWasher uses centrifugation instead of aspiration to remove liquids from all plate formats, including 1536w, eliminating background and variability at their (assay) sources. Highly reproducible residual volumes 10x lower than conventional plate washers enable imagers to produce cleaner images, raising z' 0.1-0.3 for typical adherent cellular assays. Higher z' means to miss fewer active compounds and reduce false positives to re-screen. BlueWasher immediately improves screening economics without complex assay or automation changes, delivering unparalleled ROI and direct boost to overall drug discovery productivity.
    A technical introduction into centrifugation based cell wash / media changed will be followed by a number of examples discussing improvement of data quality in HTS / HCS. Other bead based applications like nucleic acids extraction or protein binding assays will be presented as well.

    Lecture
  • Date:22MondayOctober 2018

    TBA

    More information
    Time
    14:00 - 15:00
    Title
    Special Guest Seminar
    Location
    Max and Lillian Candiotty Building
    Auditorium
    Lecturer
    Prof. Kazuhiko Nakatani
    Institute of Scientific and Industrial Research, Osaka University, Japan
    Organizer
    Department of Biological Regulation
    Contact
    Lecture
  • Date:23TuesdayOctober 201825ThursdayOctober 2018

    Modern teaching methods and soft skills development in science

    More information
    Time
    08:00 - 08:00
    Location
    David Lopatie Conference Centre
    Kimmel Auditorium
    Chairperson
    Ron Blonder
    Contact
    Conference
  • Date:23TuesdayOctober 2018

    The seeds of ice in clouds

    More information
    Time
    11:00
    Location
    Sussman Family Building for Environmental Sciences
    M. Magaritz Seminar Room
    Lecturer
    Prof. Ben Murray
    University of Leeds
    Organizer
    Department of Earth and Planetary Sciences
    Contact
    Lecture
  • Date:23TuesdayOctober 2018

    Chemical Approaches to Study Oxidative Protein Folding

    More information
    Time
    14:00 - 15:00
    Location
    Helen and Milton A. Kimmelman Building
    Dov Elad Room
    Lecturer
    Dr. Norman Metanis
    Organizer
    Department of Structural Biology
    Contact
    Lecture
  • Date:25ThursdayOctober 2018

    Hierarchical dynamics of visual inference

    More information
    Time
    12:30
    Location
    Nella and Leon Benoziyo Building for Brain Research
    Lecturer
    Prof. Jochen Braun
    Institute of Biology Otto-von-Guericke Unversity, Magdeburg
    Organizer
    Department of Neurobiology
    Contact
    DetailsShow full text description of Benoziyo Brain Research Building Room 113 Host: Prof. Dov...»
    Benoziyo Brain Research Building Room 113

    Host: Prof. Dov Sagi dov.sagi@weizmann.ac.il tel: 3747
    For assistance with accessibility issues, please contact naomi.moses@weizmann.ac.il
    AbstractShow full text abstract about Visual input is noisy, variable, and ambiguous. Optimal inf...»
    Visual input is noisy, variable, and ambiguous. Optimal inference of physical causes is challenging even for a restricted set of causes (e.g., orientations and spatial frequencies). It is well understood (e.g., Veliz-Cuba et al., 2016) that stochastic dynamical systems can approximate optimal inference by continuously accumulating and evaluating visual evidence. I will argue that the dynamics of multi-stable perception is consistent with just such an inference mechanism. Its psychophysically observable characteristics fully constrain a hierarchical dynamics with three levels, the lowest of which may conceivably correspond to cortical columns or clusters of columns. Given suitable inputs, this hierarchical dynamics accumulates and evaluates noisy evidence to make nearly optimal categorical discriminations. Moreover, its dynamical features seem to afford functional benefits in a volatile world, such as balancing stability and sensitivity of inference.

    References:
    Cao, Pastukhov, Mattia, Braun (2016) Collective activity of many bistable assemblies reproduces characteristic dynamics of multistable perception. J. Neurosci., 36: 6957-72.

    Veliz-Cuba, Kilpatrick, Josic (2016) Stochastic models of evidence accumulation in changing environments. SIAM Review, 58: 264-289.

    Lecture
  • Date:25ThursdayOctober 2018

    Development of placenta-derived (PLX) cell therapy- from bench- to bedside

    More information
    Time
    14:00 - 15:00
    Title
    Special Guest Lecture
    Location
    Max and Lillian Candiotty Building
    Auditorium
    Lecturer
    Dr. Racheli Ofir
    Vice President Research & Intellectual Property, {Pluristem, MATAM, Haifa
    Organizer
    Department of Biological Regulation
    Contact
    AbstractShow full text abstract about PLacental expanded (PLX) cells are placenta-derived, mesench...»
    PLacental expanded (PLX) cells are placenta-derived, mesenchymal-like adherent stromal cells expanded using a bioreactor system which provides a three dimensional (3D) micro-environment enabling tightly controlled expansion. Accumulated data from multiple in vitro and in vivo experiments indicate that these cells act via a paracrine or endocrine manner to facilitate healing of damaged tissue.
    Pluristem’s two lead placenta-derived cell products, PLX-PAD and PLX-R18, are each in clinical development for several indications. PLX-Immune is in non-clinical development stages for Cancer. Data from non-clinical as well as clinical studies will be presented.
    Lecture
  • Date:25ThursdayOctober 2018

    Pelletron meeting - by invitation only

    More information
    Time
    16:00 - 17:30
    Contact
    Lecture
  • Date:28SundayOctober 201801ThursdayNovember 2018

    SAAC meeting

    More information
    Title
    Scientific and Academic Advisory Committee meeting 2018
    Contact
    International Board
  • Date:28SundayOctober 201802FridayNovember 2018

    International Board SAAC Review

    More information
    Contact
    Academic Events
  • Date:28SundayOctober 2018

    The Ideal Solution to Interactively Analyze Microscopy Images

    More information
    Time
    10:30
    Location
    Max and Lillian Candiotty Building
    Auditorium
    Lecturer
    Georgia Golfis
    BITPLANE
    Organizer
    Department of Life Sciences Core Facilities
    Contact
    DetailsShow full text description of General Presentation & live demo Imaris Training 28...»
    General Presentation & live demo

    Imaris Training 28-29 October 2018
    For training please register - ofra.golani@weizmann.ac.il
    Lecture
  • Date:29MondayOctober 201801ThursdayNovember 2018

    International Board SAAC Review

    More information
    Contact
    DetailsShow full text description of Review subjects - High Energy Theory and Experiment Organi...»
    Review subjects -
    High Energy Theory and Experiment
    Organic Chemistry and Material Science
    Developmental Biology and Regenerative Medicine
    Academic Events
  • Date:31WednesdayOctober 2018

    Developmental Club Series 2018-2019

    More information
    Time
    10:00
    Location
    Camelia Botnar Building
    Botnar Auditorium
    Lecturer
    Karina Yaniv
    Organizer
    Department of Molecular Genetics
    Developmental Club
    Contact
    Lecture

Pages